(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Doctor's orders? ‘Belly laugh at least two to five days a week' - 2How a rare drug made from scientists' blood saves babies from botulism
- 3Cygnus XL brings cargo to the ISS for 1st time | Space photo of the day for Dec. 1, 2025
- 4Europe must reinvent warfare for ‘era of shocks,’ NATO’s Vandier says
- 5Luigi Mangione‘s lawyers say Bondi’s death penalty decision was tainted by conflict of interest
- Watch the Geminid meteor shower peak tonight from the comfort of home with this free livestream
- Feeling wonder every day improves our health. Here’s how to do it.
- EPA watchdog finds nation’s most contaminated sites are vulnerable to flooding, wildfires
- Top 5 Top of the line Books of the Year
- Pick Your Number one sort of blossom
- Step by step instructions to Streamline Your Dozing Involvement in a Savvy Bed
- Instructions to Pick the Right Senior Protection Plan.
- Pain at the pump for Hampton Roads residents
- Find the Historical backdrop of the Modern Unrest: Changing Society and Innovation
